Citation Impact
Citing Papers
Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America
2009 Standout
Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19
2020 Standout
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
2007 Standout
Empiric Combination Antibiotic Therapy Is Associated with Improved Outcome against Sepsis Due to Gram-Negative Bacteria: a Retrospective Analysis
2010
Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society
2016 Standout
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2014 Standout
Efficacy of Therapy with Recombinant Human Activated Protein C of Critically Ill Surgical Patients with Infection Complicated by Septic Shock and Multiple Organ Dysfunction Syndrome
2011
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2014 Standout
Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial
2009 Standout
Effect of Sedation With Dexmedetomidine vs Lorazepam on Acute Brain Dysfunction in Mechanically Ventilated Patients
2007 Standout
Long-term Cognitive Impairment and Functional Disability Among Survivors of Severe Sepsis
2010 Standout
Dexmedetomidine vs Midazolam for Sedation of Critically Ill Patients<subtitle>A Randomized Trial</subtitle>
2009 Standout
Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications
2015 Standout
The re-emergence of natural products for drug discovery in the genomics era
2015 Standout
Perspectives on Daptomycin Resistance, with Emphasis on Resistance in Staphylococcus aureus
2007
Current Treatment Options for Community‐Acquired Methicillin‐ResistantStaphylococcus aureusInfection
2008
Safety and Efficacy of Corticosteroids for the Treatment of Septic Shock: A Systematic Review and Meta‐Analysis
2009
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
2020 Standout
Antimicrobial Resistance in the Intensive Care Unit: Mechanisms, Epidemiology, and Management of Specific Resistant Pathogens
2010
Methicillin-resistant Staphylococcus aureus-induced thrombo-inflammatory response is reduced with timely antibiotic administration
2013
Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults
2007 Standout
Incidence, characteristics and outcomes of patients with severe community acquired-MRSA pneumonia
2009
Nonsteroidal Antiinflammatory Drugs May Affect the Presentation and Course of Community-Acquired Pneumonia
2010
Is Methicillin Resistance Associated with a Worse Prognosis in Staphylococcus aureus Ventilator-Associated Pneumonia?
2005
Delirium in elderly people
2013 Standout
Drotrecogin Alfa (Activated) in Adults with Septic Shock
2012 Standout
Factors Associated with the Outcome of Life-Threatening Necrotizing Pneumonia due to Community-Acquired <i>Staphylococcus aureus</i> in Adult and Adolescent Patients
2010
Invasive approaches to the diagnosis of ventilator-associated pneumonia: A meta-analysis
2005
Health Care-Associated Pneumonia (HCAP)
2011
Before–after study of a standardized hospital order set for the management of septic shock*
2006
Extended Evaluation of Recombinant Human Activated Protein C United States Trial (ENHANCE US)
2004
Delirium as a Predictor of Mortality in Mechanically Ventilated Patients in the Intensive Care Unit
2004 Standout
The effect of age on the development and outcome of adult sepsis*
2005
Protein C/activated protein C pathway: Overview of clinical trial results in severe sepsis
2004
Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy
2013 Standout
Severe Sepsis and Septic Shock
2013 Standout
Waves of resistance: Staphylococcus aureus in the antibiotic era
2009 Standout
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
2008 Standout
Effective Antibiotic Treatment Prescribed by Emergency Physicians in Patients Admitted to the Intensive Care Unit with Severe Sepsis or Septic Shock: Where is the Gap?
2011
Bad Bugs Need Drugs: An Update on the Development Pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America
2006 Standout
Frontline antibiotic therapy
2013
Human recombinant activated protein C for severe sepsis
2012
Methicillin-Resistant Staphylococcus aureus: An Evolutionary, Epidemiologic, and Therapeutic Odyssey
2005
Sepsis and septic shock
2018 Standout
BTS guidelines for the management of community acquired pneumonia in adults: update 2009
2009
The Immunopathogenesis of Sepsis in Elderly Patients
2005
How Important is Methicillin-Resistant Staphylococcus aureus as a Cause of Community-Acquired Pneumonia and What is Best Antimicrobial Therapy?
2012
Time to Initiation of Fluconazole Therapy Impacts Mortality in Patients with Candidemia: A Multi‐Institutional Study
2006 Standout
Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets
2008 Nature
Long-Term Cognitive Impairment after Critical Illness
2013 Standout
Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens
2010
Treatment of hospital-acquired pneumonia with linezolid or vancomycin: a systematic review and meta-analysis
2013
Community-Acquired Pneumonia Requiring Admission to an Intensive Care Unit
2007
The Rationale for Revising the Clinical and Laboratory Standards Institute Vancomycin Minimal Inhibitory Concentration Interpretive Criteria for Staphylococcus aureus
2007
Septic Shock Attributed to Candida Infection: Importance of Empiric Therapy and Source Control
2012
Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial
2010 Standout
New antimicrobial agents as therapy for resistant gram-positive cocci
2007
Hospital-Acquired Infections Due to Gram-Negative Bacteria
2010 Standout
Point: Vancomycin Is Not Obsolete for the Treatment of Infection Caused by Methicillin-Resistant Staphylococcus aureus
2007
Infection Rate and Acute Organ Dysfunction Risk as Explanations for Racial Differences in Severe Sepsis
2010
The immunopathology of sepsis and potential therapeutic targets
2017 Standout
Validation and clinical implications of the IDSA/ATS minor criteria for severe community-acquired pneumonia
2009
The Artificial Intelligence Clinician learns optimal treatment strategies for sepsis in intensive care
2018 Standout
Pragmatic management of Panton–Valentine leukocidin-associated staphylococcal diseases
2011
The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis *
2004
Linezolid in Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia: A Randomized, Controlled Study
2012
The acute respiratory distress syndrome
2012 Standout
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Skin and Soft-Tissue Infections Caused by Methicillin-ResistantStaphylococcus aureus
2007
Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders
2011 Standout
Multidrug efflux pumps: structure, function and regulation
2018 Standout
Prognosis of community acquired pneumonia (CAP): Value of triggering receptor expressed on myeloid cells-1 (TREM-1) and other mediators of the inflammatory response
2007 Standout
Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America
2019 Standout
Impact of Methicillin Resistance on Outcome of Staphylococcus aureus Ventilator-associated Pneumonia
2004
Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management
2015 Standout
Systemic Host Responses in Severe Sepsis Analyzed by Causative Microorganism and Treatment Effects of Drotrecogin Alfa (Activated)
2003
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
2016 Standout
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
2020 Standout
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
2011 Standout
Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children
2011 Standout
Pseudomonas aeruginosaBloodstream Infection: Importance of Appropriate Initial Antimicrobial Treatment
2005
Response to Emerging Infection Leading to Outbreak of Linezolid-Resistant Enterococci
2007
Invasive Candidiasis
2015 Standout
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
2015 Standout
Delaying the Empiric Treatment of Candida Bloodstream Infection until Positive Blood Culture Results Are Obtained: a Potential Risk Factor for Hospital Mortality
2005 Standout
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2020 Standout
Burn Wound Infections
2006 Standout
Community-Associated Methicillin-ResistantStaphylococcus aureus: Epidemiology and Clinical Consequences of an Emerging Epidemic
2010 Standout
Reply to Taccone et al, Wolff and Mourvillier, Masuta and Iwata, and Lahey
2012
Sepsis: Multiple Abnormalities, Heterogeneous Responses, and Evolving Understanding
2013
Physiology of Microglia
2011 Standout
New antimicrobial agents for the treatment of Gram-positive bacterial infections
2008
Works of Becky Bates being referenced
Safety of Drotrecogin Alfa (Activated) in Surgical Patients with Severe Sepsis
2004
Steroid use in PROWESS severe sepsis patients treated with drotrecogin alfa (activated)
2005
Severe community-acquired pneumonia as a cause of severe sepsis: Data from the PROWESS study*
2005
The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results*
2003
Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis
2004
A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: Comparison with a controlled clinical trial*
2008
Drotrecogin Alfa (Activated) Treatment of Older Patients with Severe Sepsis
2003
Drotrecogin Alfa (activated) Improves In-hospital and 90-day Survival in Patients With Severe Sepsis and Community-acquired Pneumoni
2003